Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
New Data from Physiological-Based Pharmacokinetic (PBPK) Model Supports APX3330 Oral Dose for the Ongoing ZETA-1 Phase 2 Trial […]